<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Targeting CD47: A Novel Immunotherapy Approach Against Cancer

The Landscape of CD47 Expression in Tumor Cells Predicts Macrophage-Mediated Phagocytosis in Immuno-Oncology Therapy

Huajun Yang, Zhongliang Li, Beibei Tang, Danting Yan, Weibin Tan*, Xiaoyan Fu*, Frank Xing, and Qian Shi

*Suzhou Blood Center Taicang , Jiangsu, China

CrownBio 2017. Poster: Targeting CD47: A Novel Immunotherapy Approach Against CancerMost human tumors express CD47 to escape macrophage surveillance. Therefore targeting CD47 to reinstate macrophage functionality in clearing tumor cells is an important immuno-oncology strategy.

To support research into novel anti-CD47 agents, robust preclinical platforms including in vitro assays are required. Crown Bioscience has consequently developed a macrophage differentiation system followed by M1/M2 activation.

This assay co-cultures activated macrophages with target tumor cells and labeling for flow cytometry, allowing the phagocytic effects of anti-CD47 agents and other related immunotherapeutics to be assessed.

Read this Poster to Discover:

  • How CD47 expression level varies in different cancer cell models, and that Karpas299 is a valid alternative to SK-OV-3 in phagocytosis studies, expressing more CD47 and inducing more robust target engulfing activity.

  • That M1 and M2 macrophages demonstrate anti-CD47 antibody specific phagocytic activities, whereas anti-PD-L1 treatment is comparable with controls.

  • That disrupting the CD47-SIRPa anti-phagocytic axis is a novel immunotherapy approach against cancer.

Download the Poster Now!



Download Now

Your privacy is important to us.
We'll never share your information.